Pathos AI stories

Pathos AI Signs Two Major Breast Cancer Drug Licensing Deals Worth Over $2B, Plans $3B Series E

Pathos AI announced two significant licensing agreements for breast cancer treatments: a $2.2 billion deal with China's Alphamab Oncology for bispecific ADC JSKN016 targeting triple-negative breast cancer, and a co-exclusive agreement with AstraZeneca for ERα degrader AZD4241 for ER-positive breast cancer. The company is reportedly planning to raise a Series E round at a $3 billion valuation.